Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2009 Sep;52(9):1971-3.
doi: 10.1007/s00125-009-1452-2. Epub 2009 Jul 16.

Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, open-label study

J Rosenstock, V Fonseca, J B McGill, M Riddle, J P Hallé, I Hramiak, P Johnston, M Davis
Randomized Controlled Trial

Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, open-label study

J Rosenstock et al. Diabetologia. 2009 Sep.
No abstract available

PubMed Disclaimer

References

    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'PMC', 'value': 'PMC2723680', 'is_inner': False, 'url': 'https://pmc.ncbi.nlm.nih.gov/articles/PMC2723680/'}, {'type': 'PubMed', 'value': '19526210', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/19526210/'}]}
    2. Rosenstock J, Fonseca V, McGill JB et al (2009) Similar progression of diabetic retinopathy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: a long-term, randomised, open-label study. Diabetologia. doi:10.1007/s00125-009-1415-7 - PMC - PubMed
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'PubMed', 'value': '19572116', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/19572116/'}]}
    2. Currie CJ, Poole CD, Gale EAM (2009) The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia. doi:10.1007/s00125-009-1440-6 - PubMed
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'PMC', 'value': 'PMC2723679', 'is_inner': False, 'url': 'https://pmc.ncbi.nlm.nih.gov/articles/PMC2723679/'}, {'type': 'PubMed', 'value': '19565214', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/19565214/'}]}
    2. Hemkens LG, Grouven U, Bender R et al (2009) Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia. doi:10.1007/s00125-009-1418-4 - PMC - PubMed
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'PMC', 'value': 'PMC2723678', 'is_inner': False, 'url': 'https://pmc.ncbi.nlm.nih.gov/articles/PMC2723678/'}, {'type': 'PubMed', 'value': '19603149', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/19603149/'}]}
    2. Colhoun HM, SDRN Epidemiology Group (2009) Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group. Diabetologia. doi:10.1007/s00125-009-1453-1 - PMC - PubMed
    1. Jonasson JM, Ljung R, Talbäck M, Haglund B, Gudbjörnsdòttir S, Steineck G (2009) Insulin glargine use and short-term incidence of malignancies—a population-based follow-up study in Sweden. doi:10.1007/s00125-009-1444-2 - PubMed

MeSH terms